Jger et al
McGowan warns that comparing the lipolytic effects of each medication based on the results of different studies can cause validity issues due to differing patient populations
Many patients with type 2 diabetes or weight management goals ask whether they need both drugs, and the answer depends on individual metabolic factors, blood sugar patterns, and treatment response
When patients are prescribed semaglutide treatments by their licensed healthcare professional or a telehealth provider, they are entitled to receive authentic, FDA-approved and regulated Wegovy," Dave Moore, Novo Nordisk's executive vice president of U.S
CNS = central nervous system
Retatrutide, a novel peptide currently being investigated for its potential in metabolic and weight-related studies, is no exception